Skip to main content
SpringerLink
Log in

Traitements de rattrapage du cancer bronchique non à petites cellules

  • Chapter
Oncologie thoracique

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 387 Accesses

Résumé

Les traitements de premiére ligne chez les patients porteurs de cancers bronchiques non à petites cellules (CBNPC) métastatiques ont montré leur intérêt en termes de survie et de qualité de vie. Malgré ces progrès, souvent associés à un allongement de la survie sans progression, la totalité des patients progresse dans un second temps et relève donc d’un traitement de deuxième ligne.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Hensing TA, Schell MJ, Lee JH, Socinski MA (2005) Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer 47: 253–259

    Article  PubMed  Google Scholar 

  2. Shepherd FA, Dancey J, Ramlau R et al. (2000) Prospective randomized trial of docetaxel vs best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: J Clin Oncol 18: randomize

    Google Scholar 

  3. Dancey J, Shepherd FA, Gralla RJ, Kim YS (2004) Quality of life assessment of second-line docetaxel vs best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43: 183–194

    Article  PubMed  Google Scholar 

  4. Fossella FV, DeVore R, Kerr RN et al. (2000) Randomized phase III trial of docetaxel vs vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354–2362

    PubMed  CAS  Google Scholar 

  5. Gridelli C, Gallo C, Di Maio M et al. (2004) A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small cell lung cancer. The DISTAL 01 study. Br J Cancer 9: 1996–2004

    Article  Google Scholar 

  6. Bria E, Cuppone F, Ciccarese M et al. (2006) Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 32: 583–587

    Article  PubMed  CAS  Google Scholar 

  7. Di Maio M, Perrone F, Chiodini P et al. (2007) Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small cell lung cancer. J Clin Oncol 25: 1377–1382

    Article  PubMed  Google Scholar 

  8. Hanna N, Shepherd F, Fossella F, Pereira J (2004) Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589–1597

    Article  PubMed  CAS  Google Scholar 

  9. Weiss GJ, Langer C, Rosell R et al. (2006) Elderly patients benefit from second line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 24: 4405–4411

    Article  PubMed  CAS  Google Scholar 

  10. Scagliotti G, Hanna N, Fossella F et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14: 253–263

    Article  PubMed  CAS  Google Scholar 

  11. Smit EF, Burgers SA, Biesma B et al. (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27: 2038–2045

    Article  PubMed  CAS  Google Scholar 

  12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

    Article  PubMed  CAS  Google Scholar 

  13. Thatcher N, Chang A, Parikh P et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537

    Article  PubMed  CAS  Google Scholar 

  14. Maruyama R, Nishiwaki Y, Tamura T et al. (2008) Phase III study, V-15-32, of gefitinib vs docetaxel in previously treated Japanese patients with non-small cell lung cancer. J Clin Oncol 26: 4244–4252

    Article  PubMed  CAS  Google Scholar 

  15. Kim ES, Hirsh V, Mok T et al. (2008) Gefitinib vs docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809–1818

    Article  PubMed  CAS  Google Scholar 

  16. Heymach JV, Johnson BE, Prager D et al. (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25: 4270–4277

    Article  PubMed  CAS  Google Scholar 

  17. Natale RB, Bodkin D, Govindan R et al. (2009) Vandetanib vs gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 27: 2523–2529

    Article  PubMed  CAS  Google Scholar 

  18. Schiller JH, Larson T, Ou SH et al. (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27: 3836–3841

    Article  PubMed  Google Scholar 

  19. Blumenschein GR Jr, Gatzemeier U, Fossella F et al. (2009) Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27: 4274–4280

    Article  PubMed  CAS  Google Scholar 

  20. Socinski MA, Novello S, Brahmer JR et al. (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650–656

    Article  PubMed  CAS  Google Scholar 

  21. Reid T, Valone F, Lipera W et al. (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45: 381–386

    Article  PubMed  Google Scholar 

  22. Douillard JY, Shepherd FA, Hirsh V et al. (2010) Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. J Clin Oncol 28: 744–752

    Article  PubMed  CAS  Google Scholar 

  23. Tsao MS, Sakurada A, Cutz JC et al. (2005) Erlotinib in lung cancer — molecular and clinical predictors of outcome. N Engl J Med 353: 133–144

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de pneumologie, Hôpital Larrey CHU Toulouse Chemin de Pouvourville, 31059, Toulouse Cedex

    G. Plat & J. Mazières

Authors
  1. G. Plat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Mazières
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Plat, G., Mazières, J. (2011). Traitements de rattrapage du cancer bronchique non à petites cellules. In: Oncologie thoracique. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-99041-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-99041-0_10

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-99040-3

  • Online ISBN: 978-2-287-99041-0

Publish with us

Policies and ethics

Search

Navigation